VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Fundamental Analysis

BIT:1VRTX • US92532F1003

334.7 EUR
-2.05 (-0.61%)
Last: Sep 10, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

Overall 1VRTX gets a fundamental rating of 7 out of 10. We evaluated 1VRTX against 77 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1VRTX a very profitable company, without any liquidiy or solvency issues. 1VRTX is growing strongly while it also seems undervalued. This is an interesting combination This makes 1VRTX very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • 1VRTX had positive earnings in the past year.
  • In the past year 1VRTX had a positive cash flow from operations.
  • Of the past 5 years 1VRTX 4 years were profitable.
  • 1VRTX had a positive operating cash flow in 4 of the past 5 years.
1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • 1VRTX has a better Return On Assets (15.13%) than 86.84% of its industry peers.
  • 1VRTX's Return On Equity of 21.18% is amongst the best of the industry. 1VRTX outperforms 88.16% of its industry peers.
  • With an excellent Return On Invested Capital value of 16.69%, 1VRTX belongs to the best of the industry, outperforming 90.79% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for 1VRTX is significantly above the industry average of 11.65%.
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROIC 16.69%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
1VRTX.MI Yearly ROA, ROE, ROIC1VRTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • The Profit Margin of 1VRTX (31.86%) is better than 86.84% of its industry peers.
  • The Operating Margin of 1VRTX (38.77%) is better than 92.11% of its industry peers.
  • In the last couple of years the Operating Margin of 1VRTX has grown nicely.
  • Looking at the Gross Margin, with a value of 86.11%, 1VRTX is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 1VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
1VRTX.MI Yearly Profit, Operating, Gross Margins1VRTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • 1VRTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for 1VRTX has been reduced compared to 1 year ago.
  • The number of shares outstanding for 1VRTX has been reduced compared to 5 years ago.
  • The debt/assets ratio for 1VRTX has been reduced compared to a year ago.
1VRTX.MI Yearly Shares Outstanding1VRTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
1VRTX.MI Yearly Total Debt VS Total Assets1VRTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • There is no outstanding debt for 1VRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.73
WACC9.67%
1VRTX.MI Yearly LT Debt VS Equity VS FCF1VRTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.52 indicates that 1VRTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.52, 1VRTX is in line with its industry, outperforming 57.89% of the companies in the same industry.
  • 1VRTX has a Quick Ratio of 2.16. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.16, 1VRTX is in line with its industry, outperforming 59.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.16
1VRTX.MI Yearly Current Assets VS Current Liabilites1VRTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • 1VRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 7966.67%, which is quite impressive.
  • Measured over the past years, 1VRTX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
  • 1VRTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.46%.
  • The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%

3.2 Future

  • 1VRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 150.73% yearly.
  • The Revenue is expected to grow by 10.01% on average over the next years. This is quite good.
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1VRTX.MI Yearly Revenue VS Estimates1VRTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B 20B
1VRTX.MI Yearly EPS VS Estimates1VRTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.19, the valuation of 1VRTX can be described as rather expensive.
  • Based on the Price/Earnings ratio, 1VRTX is valued cheaper than 80.26% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.10. 1VRTX is around the same levels.
  • With a Price/Forward Earnings ratio of 18.76, 1VRTX is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, 1VRTX is valued cheaper than 81.58% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of 1VRTX to the average of the S&P500 Index (28.06), we can say 1VRTX is valued slightly cheaper.
Industry RankSector Rank
PE 23.19
Fwd PE 18.76
1VRTX.MI Price Earnings VS Forward Price Earnings1VRTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 1VRTX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1VRTX is cheaper than 76.32% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1VRTX is valued a bit cheaper than 78.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 28.78
EV/EBITDA 20.39
1VRTX.MI Per share data1VRTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1VRTX has an outstanding profitability rating, which may justify a higher PE ratio.
  • 1VRTX's earnings are expected to grow with 329.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y749.77%
EPS Next 3Y329.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1VRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

BIT:1VRTX (9/10/2025, 7:00:00 PM)

334.7

-2.05 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04
Earnings (Next)11-03
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap85.81B
Revenue(TTM)11.42B
Net Income(TTM)3.64B
Analysts75.9
Price Target416.5 (24.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-5.11%
PT rev (3m)-11.39%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0.71%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)1.43%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 23.19
Fwd PE 18.76
P/S 8.82
P/FCF 28.78
P/OCF 26.18
P/B 5.86
P/tB 6.43
EV/EBITDA 20.39
EPS(TTM)14.43
EY4.31%
EPS(NY)17.84
Fwd EY5.33%
FCF(TTM)11.63
FCFY3.47%
OCF(TTM)12.78
OCFY3.82%
SpS37.95
BVpS57.08
TBVpS52.02
PEG (NY)0
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROCE 22.25%
ROIC 16.69%
ROICexc 24.57%
ROICexgc 27.69%
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
FCFM 30.65%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
ROICexc(3y)46.18%
ROICexc(5y)52.12%
ROICexgc(3y)66.07%
ROICexgc(5y)80.93%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 173.52%
Cap/Sales 3.04%
Interest Coverage 260.41
Cash Conversion 83.13%
Profit Quality 96.21%
Current Ratio 2.52
Quick Ratio 2.16
Altman-Z N/A
F-Score6
WACC9.67%
ROIC/WACC1.73
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / 1VRTX.MI FAQ

Can you provide the ChartMill fundamental rating for VERTEX PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 7 / 10 to 1VRTX.MI.


What is the valuation status for 1VRTX stock?

ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (1VRTX.MI). This can be considered as Fairly Valued.


What is the profitability of 1VRTX stock?

VERTEX PHARMACEUTICALS INC (1VRTX.MI) has a profitability rating of 7 / 10.


What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (1VRTX.MI) stock?

The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (1VRTX.MI) is 23.19 and the Price/Book (PB) ratio is 5.86.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (1VRTX.MI) is 7 / 10.